EUCTR2005-005877-31-IT
Active, not recruiting
Not Applicable
Phase II study Systemic treatment with ZK219477 EPOTHILONE in recurrent Glioblastoma patients - ND
ISTITUTO NEUROLOGICO CARLO BESTA0 sites15 target enrollmentApril 7, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Recurrent Glioblastoma
- Sponsor
- ISTITUTO NEUROLOGICO CARLO BESTA
- Enrollment
- 15
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Histologically proven at diagnosis GMB \- Age 18\-70 years \- KPS 70 \- Life expectancy of at least 3 months \- Presence of at least one bi\-dimensionally measurable lesion on gadolinium Gd \-enhanced MRI, indicating progressive or recurrent disease at least 8 weeks after standard external\-beam radiotherapy \- Recurrence or progression after treatment with radiotherapy and temozolomide. Also patients with residual disease after surgery for recurrent GBM will be included \- Adequate bone marrow reserve leucocytes 3,500/ml, ANC 1,500, platelets 100,000/ml ; normal baseline liver serum bilirubin 20umol/L , renal serum creatinine 150umol/L and cardiac function \- Absence of infectious disease, debilitatig chronic diseases, known psychiatric disorders \- Corticosteroid dose stable for at least 1 week \- Adequate recovery from previous surgery, radiation and chemotherapy \- Negative pregnancy test at enrolment in females of chil\-bearing potential \- Agreement to use effective contraception methods in adults of reproductive potential \- Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •\- Pregnancy \- Chemotherapy or radiotherapy within 4 weeks before screening \- History of allergic reactions due to compounds of similar chemical or biologic composition to ZK219477 \- Uncontrolled intercurrent illness including, but not limited, to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrythmia or psychiatric illness/social situations that would limit compliance with study requirements \- HIV infection \- Any prior treatment with epothilones, other tubulin\-targetting as taxanes e. paclitaxel, docetaxel and vinca alcaloids e.g. vincristine, vinblastine, vinorelbine \- Peripheral neuropathy \- Any concurrent malignancy other than non\-melanoma skin cancer or carcinoma in situ of the cervix \- Active infection \- Breast\-feeding \- Subjects who have received an experimental drug or have participated in a clinical trial within 3 months prior to screening \- Employees of the investigator or study centre with direct involvement in the proposed study or other studies under the direction of thet investigator or study centre
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Epothilone in Recurrent Glioblastoma PatientsGlioblastomaNCT00397072Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta15
Active, not recruiting
Phase 1
Phase II Study of ZK 219477 in patients with recurrent glioblastomaEUCTR2006-001659-37-GBEuropean Organisation for Research and Treatment of Cancer
Active, not recruiting
Phase 1
Phase II Study of ZK 219477 in patients with recurrent glioblastomaPhase II study of ZK 219477 in patients with recurrent glioblastoma.MedDRA version: 8.1Level: LLTClassification code 10018336Term: GlioblastomaEUCTR2006-001659-37-DEEuropean Organisation for Research and Treatment of Cancer
Active, not recruiting
Phase 1
Phase II Study of ZK 219477 in patients with recurrent glioblastomaPhase II study of ZK 219477 in patients with recurrent glioblastoma.MedDRA version: 8.1Level: LLTClassification code 10018336Term: GlioblastomaEUCTR2006-001659-37-NLEuropean Organisation for Research and Treatment of Cancer
Active, not recruiting
Phase 1
Phase II Study of ZK 219477 in patients with recurrent glioblastomaEUCTR2006-001659-37-FREuropean Organisation for Research and Treatment of Cancer